BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28267273)

  • 21. Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.
    Iida Y; Salomon MP; Hata K; Tran K; Ohe S; Griffiths CF; Hsu SC; Nelson N; Hoon DSB
    BMC Cancer; 2018 Oct; 18(1):1054. PubMed ID: 30373548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Genomic Profiling of Acral Melanoma.
    Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
    J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
    Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic and transcriptomic landscape of conjunctival melanoma.
    Cisarova K; Folcher M; El Zaoui I; Pescini-Gobert R; Peter VG; Royer-Bertrand B; Zografos L; Schalenbourg A; Nicolas M; Rimoldi D; Leyvraz S; Riggi N; Moulin AP; Rivolta C
    PLoS Genet; 2020 Dec; 16(12):e1009201. PubMed ID: 33383577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of recurrent mutational events in anorectal melanoma.
    Yang HM; Hsiao SJ; Schaeffer DF; Lai C; Remotti HE; Horst D; Mansukhani MM; Horst BA
    Mod Pathol; 2017 Feb; 30(2):286-296. PubMed ID: 27739435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Varying Mutational Alterations in Multiple Primary Melanomas.
    Egberts F; Bohne AS; Krüger S; Hedderich J; Rompel R; Haag J; Röcken C; Hauschild A
    J Mol Diagn; 2016 Jan; 18(1):75-83. PubMed ID: 26607775
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling.
    Zou Z; Ou Q; Ren Y; Lv Q; Qin L; Zhao L; Su S; Wu X; Bao H; Wang A; Zhu D; Wang X; Shao YW; Liu B
    Pigment Cell Melanoma Res; 2020 Jul; 33(4):601-611. PubMed ID: 31944535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.
    Garman B; Anastopoulos IN; Krepler C; Brafford P; Sproesser K; Jiang Y; Wubbenhorst B; Amaravadi R; Bennett J; Beqiri M; Elder D; Flaherty KT; Frederick DT; Gangadhar TC; Guarino M; Hoon D; Karakousis G; Liu Q; Mitra N; Petrelli NJ; Schuchter L; Shannan B; Shields CL; Wargo J; Wenz B; Wilson MA; Xiao M; Xu W; Xu X; Yin X; Zhang NR; Davies MA; Herlyn M; Nathanson KL
    Cell Rep; 2017 Nov; 21(7):1936-1952. PubMed ID: 29141224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
    Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
    J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of SDHD promoter mutations in various types of melanoma.
    Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
    Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic and Transcriptomic Analyses of NF1-Mutant Melanoma Identify Potential Targeted Approach for Treatment.
    Jour G; Illa-Bochaca I; Ibrahim M; Donnelly D; Zhu K; Miera EV; Vasudevaraja V; Mezzano V; Ramswami S; Yeh YH; Winskill C; Betensky RA; Mehnert J; Osman I
    J Invest Dermatol; 2023 Mar; 143(3):444-455.e8. PubMed ID: 35988589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma.
    Yang C; Sanchez-Vega F; Chang JC; Chatila WK; Shoushtari AN; Ladanyi M; Travis WD; Busam KJ; Rekhtman N
    Mod Pathol; 2020 Nov; 33(11):2244-2255. PubMed ID: 32581366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct sets of genetic alterations in melanoma.
    Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
    N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of mitogen-activated protein targeting in melanoma beyond BRAFV600.
    Sullivan RJ
    Curr Opin Oncol; 2016 Mar; 28(2):185-91. PubMed ID: 26844986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.